// App-Quantinova.ai

e13552 : Absolute bioavailability, mass balance, elimination route, and metabolite profile of the selective oral MEK1/2 inhibitor pimasertib in cancer patients.

Researchers

Presenter

  • Giorgio Massimini

Principal Investigators

  • Istvan Udvaros

  • Elmar Wimmer

  • Oliver von Richter

  • Andreas Johne

Medical Centers

  • Global Research and Early Development, Merck KGaA, Darmstadt, Germany

  • Merck KGaA, Clinical Pharmacology, Darmstadt, GermanyPRA International, Budapest, HungaryMerck KGaA, Darmstadt, Germany

  • Merck KGaA, Grafing, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Dual specificity mitogen-activated protein kinase kinase 1

Drug/Treatment

  • Pimasertib

Outcome

  • Positive

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01713036

Sponsors

  • Merck KGaA

  • Merck

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved